Literature DB >> 21741270

Tolerogenic dendritic cells and their role in transplantation.

Mohamed Ezzelarab1, Angus W Thomson.   

Abstract

The pursuit of clinical transplant tolerance has led to enhanced understanding of mechanisms underlying immune regulation, including the characterization of immune regulatory cells, in particular antigen-presenting cells (APC) and regulatory T cells (Treg), that may play key roles in promoting operational tolerance. Dendritic cells (DC) are highly efficient APC that have been studied extensively in rodents and humans, and more recently in non-human primates. Owing to their ability to regulate both innate and adaptive immune responses, DC are considered to play crucial roles in directing the alloimmune response towards transplant tolerance or rejection. Mechanisms via which they can promote central and peripheral tolerance include clonal deletion, the induction of Treg, and inhibition of memory T cell responses. These properties have led to the use of tolerogenic DC as a therapeutic strategy to promote organ transplant tolerance. In rodents, infusion of donor- or recipient-derived tolerogenic DC can extensively prolong donor-specific allograft survival, in association with regulation of the host T cell response. In clinical transplantation, progress has been made in monitoring DC in relation to graft outcome, including studies in operational liver transplant tolerance. Although clinical trials involving immunotherapeutic DC for patients with cancer are ongoing, implementation of human DC therapy in clinical transplantation will require assessment of various critical issues. These include cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy. With ongoing non-human primate studies focused on DC therapy, these logistics can be investigated seeking the optimal approaches. The scientific rationale for implementation of tolerogenic DC therapy to promote clinical transplant tolerance is strong. Evaluation of technical and therapeutic logistic issues is an important next step prior to the application of tolerogenic DC in clinical organ transplantation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741270      PMCID: PMC3192911          DOI: 10.1016/j.smim.2011.06.007

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  125 in total

Review 1.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.

Authors:  Markus J Barten; Jens Garbade; Hartmuth B Bittner; Martin Fiedler; Stefan Dhein; Joachim Thiery; Friedrich W Mohr; Jan F Gummert
Journal:  Int Immunopharmacol       Date:  2006-08-15       Impact factor: 4.932

3.  High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance.

Authors:  Daisuke Tokita; George V Mazariegos; Alan F Zahorchak; Nydia Chien; Masanori Abe; Giorgio Raimondi; Angus W Thomson
Journal:  Transplantation       Date:  2008-02-15       Impact factor: 4.939

4.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Authors:  Olivier Manches; David Munn; Anahita Fallahi; Jeffrey Lifson; Laurence Chaperot; Joel Plumas; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

5.  Long-term survival of limb allografts induced by pharmacologically conditioned, donor alloantigen-pulsed dendritic cells without maintenance immunosuppression.

Authors:  Ryosuke Ikeguchi; Justin M Sacks; Jignesh V Unadkat; Mario Solari; Elaine K Horibe; Angus W Thomson; Andrew W P Lee; Maryam Feili-Hariri
Journal:  Transplantation       Date:  2008-01-27       Impact factor: 4.939

6.  Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

Authors:  Wendy W J Unger; Sandra Laban; Fleur S Kleijwegt; Arno R van der Slik; Bart O Roep
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

7.  Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes.

Authors:  Abdul Tawab; Yong Fan; Elizabeth J Read; Roger J Kurlander
Journal:  Transfusion       Date:  2009-03       Impact factor: 3.157

8.  Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase.

Authors:  Gro F Flatekval; Mouldy Sioud
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

Review 9.  Intercellular transfer of MHC and immunological molecules: molecular mechanisms and biological significance.

Authors:  L A Smyth; B Afzali; J Tsang; G Lombardi; R I Lechler
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

10.  CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

Authors:  Kristin V Tarbell; Sayuri Yamazaki; Kara Olson; Priscilla Toy; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  74 in total

1.  Murine Sertoli cells promote the development of tolerogenic dendritic cells: a pivotal role of galectin-1.

Authors:  Jianxin Gao; Xujie Wang; Yunchuan Wang; Fu Han; Weixia Cai; Bin Zhao; Yan Li; Shichao Han; Xue Wu; Dahai Hu
Journal:  Immunology       Date:  2016-05-04       Impact factor: 7.397

2.  Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.

Authors:  Mohamed B Ezzelarab; Lien Lu; Hao Guo; Alan F Zahorchak; William F Shufesky; David K C Cooper; Adrian E Morelli; Angus W Thomson
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

Review 3.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 4.  Tolerogenic dendritic cells and their applications in transplantation.

Authors:  Haibin Li; Bingyi Shi
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

Review 5.  Tolerogenic dendritic cells in organ transplantation.

Authors:  Jordi Ochando; Farideh Ordikhani; Stefan Jordan; Peter Boros; Angus W Thomson
Journal:  Transpl Int       Date:  2019-10-29       Impact factor: 3.782

6.  Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.

Authors:  D Sharma; R Al-Khalidi; S Edgar; Q An; Y Wang; C Young; D Nowis; D C Gorecki
Journal:  Gene Ther       Date:  2016-12-22       Impact factor: 5.250

Review 7.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

8.  Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.

Authors:  Li Li; Liping Huang; Hong Ye; Steven P Song; Amandeep Bajwa; Sang Ju Lee; Emily K Moser; Katarzyna Jaworska; Gilbert R Kinsey; Yuan J Day; Joel Linden; Peter I Lobo; Diane L Rosin; Mark D Okusa
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 9.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

10.  IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.

Authors:  Elizabeth O Stenger; Brian R Rosborough; Lisa R Mathews; Huihui Ma; Markus Y Mapara; Angus W Thomson; Hēth R Turnquist
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.